Phase 1/2 Trial of Potential Gene Therapy for PKU Doses First Patient
News
A Phase 1/2 clinical trial evaluating BioMarin Pharmaceutical’s investigational gene therapy BMN 307 for people with phenylketonuria (PKU) has dosed its first patient. Enrollment is ongoing at the University Hospital Birmingham NHS Foundation Trust ... Read more